Merck Partners With BenevolentAI and Exscientia for AI Drug Discovery Collaborations

Merck KGaA has signed partnership deals with BenevolentAI and Exscientia for its AI-driven drug discovery push. The German science and technology company is collaborating with these AI drug discovery firms to strengthen its own capabilities in designing and creating new drugs using artificial intelligence.

As per Fierce BioTech, Merck KGaA is betting on an AI-enabled future for drug discovery the new deals with BenevolentAI and Exscientia are part of its strategy to meet its own goals. Based on the reports, the contracts are worth over $30 million upfront and up to $1 billion in possible milestone arrangements.

In any case, with its collaborations with two leading AI drug discovery groups, Merck just bolstered its chances of yielding successful results for its targeted development and production of new drugs on three leading categories in the medical fields, which are immunology, neuroinflammation, cancer, and neurology

Merck’s global head of R&D also said that the incorporation of science, AI, and data could allow them to find and produce “previously unimaginable medical breakthroughs.” Although the AI-enabled drug discovery method is still in the early stages, the company is positive that it will achieve its goals while also becoming a pioneer in this field.

“With the convergence of science, data, and AI, we're determined to fast-track the development of new and truly innovative candidates, forging a path to previously unimaginable medical breakthroughs,” Merck’s global head of research and development and chief medical officer for the healthcare business unit, Danny Bar-Zohar, said in a press release.

He added, “The partnerships with industry-leading AI technology firms BenevolentAI and Exscientia will complement our internal research capabilities and expertise, aligning with our broader strategy to enhance R&D productivity and the output of our pipeline in a sustainable manner.”

Photo by: Merck Group Media Gallery